Photograph: iStock

Belfast-based Fusion Antibodies said its performance in the second half of the year ended March 31st improved as orders and revenues significantly inc(...)

Paul Kerr, chief executive of Fusion Antibodies.

Northern Ireland contract research company Fusion Antibodies warned that revenues for the year ended March 31st would be “materially below current mar(...)

Fusion Antibodies CEO Paul Kerr said it had been a challenging period but   company had ‘turned a corner’.

Losses at Belfast pharmaceutical company Fusion Antibodies quadrupled in the six months ended September 30th compared with the same period last year, (...)

Fusion Antibodies has a particular focus on the production of antibodies in a lab. Photograph: iStock

Fusion Antibodies, the Northern Ireland contract research company, has reported losses of nearly £700,000 (€781,000) for its maiden year as an AIM-lis(...)

Fusion Antibodies, the Belfast-based contract research organisation, has issued a profit warning after it disclosed that trading for the current finan(...)

Fusion Antibodies said the outlook for the next trading year is a positive one. Photograph: iStock

Belfast pharmaceutical company Fusion Antibodies said it expects revenues for the trading year ended March 31st 2018 to grow at least 40 per cent on t(...)

Fusion Antibodies placed 6,707,317 ordinary shares on AIM at a price of £0.82

Belfast pharma company Fusion Antibodies has raised £5.5 million (€6.2m) in its debut on the junior market of the London Stock Exchange. Fusion, a c(...)

Embo Medical (from left) Wayne Allen, Colin Forde and Liam Mullins. The firm was voted “one-to watch” by the CorkBIC Venture Academy.

Embo Medical Embo Medical has created a new medical device which makes embolization procedures faster and less expensive while also offering mo(...)

  • « First
  • Prev
  • 1
  • 2